HM
BTAI icon

Howard Marks’s BioXcel Therapeutics BTAI Stock Holding History

Howard Marks’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Buy
1,380,248
+1,139,060
+472% +$1.33M 0.03% 128
2026
Q1 		$323K Hold
241,188
– – ﹤0.01% 146
2025
Q4 		$386K Hold
241,188
– – 0.01% 171
2025
Q3 		$617K Hold
241,188
– – 0.01% 164
2025
Q2 		$437K Buy
+241,188
New +$399K 0.01% 177

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Howard Marks's BTAI Position: Q2 2026 in Review

Howard Marks increased its BioXcel Therapeutics (BTAI) stake by 472% in Q2 2026, buying an estimated $1.33M and bringing the position to 1,380,248 shares worth $1.95M. The position accounts for 0.03% of the portfolio, ranked #128.

Howard Marks first reported a position in BTAI in Q2 2025 and has held it in 5 quarters since. 46 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Howard Marks held 1,380,248 shares of BioXcel Therapeutics worth $1.95M as of Q2 2026.
  • Howard Marks bought 1,139,060 BioXcel Therapeutics shares in Q2 2026, an estimated $1.33M.
  • BioXcel Therapeutics made up 0.03% of Howard Marks's portfolio in Q2 2026, its #128 holding.
  • Howard Marks first reported a position in BioXcel Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 46 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Oaktree Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.